Nkarta, Inc. (NKTA) Prices 14M Share IPO at $18/Sh

Nkarta, Inc. (NASDAQ: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the pricing of its initial public offering of 14,000,000 shares of common stock at a public offering price of $18.00 per share. Nkarta anticipates total gross proceeds of approximately $252.0 million, before deducting underwriting discounts and commissions and other offering expenses. The shares are expected to begin trading on The Nasdaq Global Select Market on July 10, 2020 under the ticker symbol "NKTX." All shares of common stock are being offered by Nkarta. The offering is expected to close on or about July 14, 2020, subject to customary closing conditions. In addition, Nkarta has granted the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of common stock at the initial public offering price.

Cowen, Evercore ISI, Stifel and Mizuho Securities are acting as joint book-running managers for the offering.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• SunPower raises $26.2M in private placement led by Sand Hill Road VCs
• Commerce chief signals end to Anthropic security rift ahead of potential IPO